| Filed On | Filing |
|---|---|
| 05 Nov 2026 | SCHEDULE 13G/A |
| 29 Oct 2026 | 10-Q |
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, October 28, 2026 -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financi... |
| 28 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
Reconciliation and tie between Trust Indenture Act of 1939 and |
| 25 Sep 2026 | 424B5 |
| 25 Sep 2026 | 424B5 |
| 24 Sep 2026 | FREE WRITING PROSPECTUS |
| 24 Sep 2026 | APPLICATION FOR DESIGNATION OF A NEW TRUSTEE |
| 23 Sep 2026 | 424B5 |
| 23 Sep 2026 | 424B5 |
| 22 Sep 2026 |
8-K: Other Events
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens |
| 07 Aug 2026 |
Form 4: Kelly-Gemmell Dorothy Elizabeth, Director
Received 6,333 shares as a grant or award · Granted 40,800 Stock Option (Right to Buy) |
| 07 Aug 2026 |
Form 3: Kelly-Gemmell Dorothy Elizabeth, Director
No securities owned |
| 30 Jul 2026 | S-3ASR |
| 29 Jul 2026 |
Form 4: Lian Brian, Director
Received 221,667 shares as a grant or award · Sold 148,517 shares ($4.95M) |
| 29 Jul 2026 |
Form 4: Zante Greg, Chief Financial Officer
Received 31,667 shares as a grant or award · Sold 21,217 shares ($710K) |
| 29 Jul 2026 |
Form 4: Mancini Marianna, Chief Operating Officer
Received 31,667 shares as a grant or award · Sold 18,217 shares ($610K) |
| 29 Jul 2026 | 10-Q |
| 29 Jul 2026 | 144 |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, July 29, 2026 -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial ... |
Loading...